KILITCH Stock Overview
Engages in the development and operation of pharmaceutical business in India.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Kilitch Drugs (India) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹367.45 |
| 52 Week High | ₹470.00 |
| 52 Week Low | ₹244.10 |
| Beta | 0.25 |
| 11 Month Change | 9.90% |
| 3 Month Change | 13.08% |
| 1 Year Change | 47.54% |
| 33 Year Change | 119.24% |
| 5 Year Change | 197.89% |
| Change since IPO | 187.74% |
Recent News & Updates
Recent updates
Kilitch Drugs (India) Limited (NSE:KILITCH) Not Flying Under The Radar
Jul 23
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly
Mar 05Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump
Feb 02We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease
Jan 30Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings
Nov 17Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why
Sep 23These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Sep 08Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors
May 05Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt
Jul 06Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today
Apr 08These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Dec 17Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?
Mar 21Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Feb 13Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?
Dec 03
Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?
Aug 20Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jul 16Shareholder Returns
| KILITCH | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -6.1% | -1.8% | 0.4% |
| 1Y | 47.5% | 61.0% | 43.9% |
Return vs Industry: KILITCH underperformed the Indian Pharmaceuticals industry which returned 61% over the past year.
Return vs Market: KILITCH exceeded the Indian Market which returned 43.9% over the past year.
Price Volatility
| KILITCH volatility | |
|---|---|
| KILITCH Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.4% |
| 10% least volatile stocks in IN Market | 3.8% |
Stable Share Price: KILITCH has not had significant price volatility in the past 3 months.
Volatility Over Time: KILITCH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 168 | Mukund Mehta | www.kilitch.com |
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of liquid ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products.
Kilitch Drugs (India) Limited Fundamentals Summary
| KILITCH fundamental statistics | |
|---|---|
| Market cap | ₹5.92b |
| Earnings (TTM) | ₹125.85m |
| Revenue (TTM) | ₹1.51b |
47.0x
P/E Ratio3.9x
P/S RatioIs KILITCH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KILITCH income statement (TTM) | |
|---|---|
| Revenue | ₹1.51b |
| Cost of Revenue | ₹804.82m |
| Gross Profit | ₹707.85m |
| Other Expenses | ₹582.01m |
| Earnings | ₹125.85m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.83 |
| Gross Margin | 46.79% |
| Net Profit Margin | 8.32% |
| Debt/Equity Ratio | 18.0% |
How did KILITCH perform over the long term?
See historical performance and comparison